Obermatt
See Similar Stocks →

Caribou Biosciences

NSQ:CRBU · US1420381089
BiotechnologySmall

360

39
Profit price10
Cash yield1
Price/Sales84
Price/Book95
Return on Capital43
Cash Return on Capital21
Return on Equity23
Profit margins12
Accruals90
Owner Earnings Margin32
Sales growth78
Profit growth44
Reinvestment59
Price momentum70
Debt load28
Refinancing23
Debt Payback1
Liquidity86
Analyst ratings75
Expectations trend50
Market mood15
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Caribou Biosciences doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2011
Employees126
Websitecariboubio.com
ISINUS1420381089
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsImmunologyStem Cell TherapyHematologyOncologyBiopharmaBiotechnologyHealth Care

Description

Caribou Biosciences, Inc. (Caribou or Caribou Biosciences) operates as a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company. The company is dedicated to developing transformative…

Analysis

Middle-of-the-road

Caribou Biosciences, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is adequate. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
86
2026

All-time high

89

Mar 2026

All-time low

86

Jun 2026

Average rank

88

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
84
—
—
—
Price/Earnings
22
—
—
—
Price/Book
95
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
97
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Caribou Biosciences with its peers
Adaptive Biotechnologies
NSQ:ADPT
20
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Tevogen Bio Holdings
NMQ:TVGN
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Kyverna Therapeutics
NSQ:KYTX
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mink Therapeutics
NAQ:INKT
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →